# PT-141 Frequently Asked Questions | Bremelanotide Explained

> PT-141 (bremelanotide) FAQ: what it is, how it works, what it does for women, how it compares to other options, and the dosing of record — answered with citations.

Direct, cited answers about PT-141 (bremelanotide) — what it is, how it works, what the trials found, and where the approval ends.

## What is PT-141 used for?

PT-141 (bremelanotide) is FDA-approved for one use: hypoactive sexual desire disorder in premenopausal women, treated with a 1.75 mg as-needed subcutaneous injection [3][7]. It is a central melanocortin MC4R agonist that acts on brain circuits for sexual desire [1]. Every other use — men, postmenopausal women, performance — is off-label or investigational [7].

## What is the PT-141 dosage for women?

The label dose of record for premenopausal women with HSDD is 1.75 mg, injected under the skin as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and eight per month [7]. This is a documented label figure carried through the Phase 3 trials [3], not a recommendation for any individual.

## Does PT-141 work?

In premenopausal women with HSDD, the Phase 3 trials showed a real but modest effect: desire rose (+0.35) and desire-related distress fell (−0.33), both statistically significant over 24 weeks [3]. Independent reviewers argue the benefit is small in everyday terms [11]. In female rats it selectively increased appetitive sexual behaviors [2]. "Works, modestly, in one approved group" is the fair answer.

## What were the results of the PT-141 clinical trials?

The two RECONNECT Phase 3 trials (1,267 women) met both coprimary endpoints: desire improved by an integrated +0.35 and desire-distress fell by −0.33, each P<.001 over 24 weeks [3]. A 52-week extension in 684 women sustained the gains with no new safety signals; nausea (40.4%), flushing, and headache were the common effects [4].

## What does PT-141 do for women?

In premenopausal women with HSDD, PT-141 modestly increases sexual desire and reduces the distress tied to low desire, as measured on validated questionnaires [3]. Brain imaging shows it does this centrally — MC4R agonism raised desire for up to 24 hours and changed how the brain processed erotic cues [5]. It is approved only for this group.

## How does PT-141 compare to flibanserin and testosterone for women?

PT-141 is an as-needed, event-driven central melanocortin agonist, whereas flibanserin is a daily centrally acting serotonergic drug and testosterone is a hormone used off-label for desire in women [10]. Reviews place melanocortins among the excitatory neuromodulators of female desire and discuss bremelanotide as a centrally acting option on that pathway [10]. Head-to-head efficacy comparisons are limited.

## What is PT-141?

PT-141 is a synthetic cyclic heptapeptide — a ring of seven amino acids — that activates the brain's MC3R and MC4R melanocortin receptors [1]. Its nonproprietary name is bremelanotide. It is a laboratory analogue of the natural peptide alpha-MSH and acts centrally on sexual-desire circuits rather than on blood vessels [1].

## What is PT-141 peptide?

"PT-141 peptide" is the same molecule named for its chemistry: a cyclic lactam heptapeptide whose seven-amino-acid ring is closed by a chemical bridge, which makes it more stable than a straight-chain peptide [7]. It is an agonist at central melanocortin receptors MC3R and MC4R [1].

## What does the PT-141 peptide do?

The PT-141 peptide switches on central melanocortin receptors (chiefly MC4R) in hypothalamic circuits, engaging dopamine pathways tied to sexual desire [1]. In animals this produced erections and lit up hypothalamic neurons; in women with HSDD it modestly raised desire and changed brain processing of erotic cues [1][5].

## Is PT-141 the same as bremelanotide?

Yes — bremelanotide is the international nonproprietary name (INN) for the molecule developed as PT-141 [7]. "PT-141" is the developmental code; "bremelanotide" is the approved-drug name. One caution: the FDA-approved bremelanotide product and material sold as "PT-141 research chemical" are not interchangeable, since the latter has no verified identity or purity [7].

## What is bremelanotide?

Bremelanotide is a melanocortin MC3R/MC4R receptor agonist — a synthetic cyclic heptapeptide analogue of alpha-MSH — approved in 2019 (NDA 210557) for HSDD in premenopausal women [7]. It acts centrally on brain circuits for sexual desire rather than on vascular tissue [1].

## How does PT-141 work?

PT-141 activates central melanocortin receptors, chiefly MC4R, in the hypothalamus and limbic system [1]. Stimulating MC4R in circuits such as the medial preoptic area is thought to engage dopamine signaling that governs sexual desire [1]. It works in the brain — not on blood vessels, which is how it differs from PDE-5 inhibitor erectile-dysfunction pills [1].

## What receptors does PT-141 act on?

PT-141 is an agonist at the melanocortin receptors MC4R and MC3R, both expressed primarily in the central nervous system [1]. MC4R in hypothalamic circuits is the main target for sexual desire [1]. It also activates MC1R in the skin peripherally, which is why repeated frequent dosing can cause hyperpigmentation [7].

## Does PT-141 work through the brain or through blood flow?

Through the brain. PT-141 acts centrally on melanocortin circuits governing sexual motivation, not peripherally on vascular smooth muscle [1]. Brain imaging in women confirmed this: MC4R agonism altered amygdala–insula connectivity and other central processing of erotic stimuli [5]. This central mechanism is its defining contrast with blood-flow erectile-dysfunction drugs [1].

## What is a melanocortin receptor agonist?

A melanocortin receptor agonist is a molecule that switches on the melanocortin receptors — a family of five (MC1R–MC5R) that respond to peptides like alpha-MSH [1]. PT-141 targets the central MC3R and MC4R subtypes, which sit in brain circuits for sexual desire and appetite [1]. "Agonist" simply means it activates the receptor rather than blocking it.

## Does PT-141 increase testosterone?

No. This is a common misconception. PT-141 does not act through the reproductive hormone (HPG) axis and does not directly raise testosterone [research record]. It works on central melanocortin (MC4R) circuits for sexual desire, a mechanism independent of testosterone [1]. It is also not a PDE-5 inhibitor and does not act on blood vessels.

## How is PT-141 different from PDE-5 inhibitors?

PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow [1]. PT-141 acts centrally, on the brain's melanocortin circuitry of sexual desire and motivation [1]. The difference is mechanism and target tissue: one is a blood-flow drug, the other a brain-desire drug [1]. They are not the same class.

## What is the PT-141 dosage?

The dose of record from the U.S. label is 1.75 mg subcutaneous, as needed, for HSDD in premenopausal women, with a maximum of one dose per 24 hours and eight per month [7]. The terminal half-life is about 2.7 hours (range 1.9–4.0 h) [7]. This is the approved label figure, not a recommendation for any person or use.

## How much PT-141 should I take?

This digest does not tell anyone how much to take. The only documented figure is the approved label dose — 1.75 mg subcutaneous as needed for premenopausal HSDD, capped at one dose per 24 hours and eight per month [7]. The product carries a contraindication in uncontrolled hypertension and cardiovascular disease [7]. We report the label dose as a fact and recommend no dose to any individual.

## How much PT-141 to inject?

The approved injection of record is 1.75 mg subcutaneous, used as needed, with a strict frequency cap of one dose per 24 hours and eight per month [7]. That is a label figure for one approved use, not an instruction. Material sold as "PT-141 research chemical" has no verified concentration, so any amount on its label is unreliable [7].

## How do you reconstitute PT-141?

This editorial digest does not provide reconstitution or preparation instructions for any peptide. The FDA-approved bremelanotide product is supplied and used per its prescribing information [7]. "PT-141 research chemical" sits outside the approval framework with no regulatory oversight of identity, purity, or concentration, so no preparation guidance is given here [7].

## How do you take PT-141?

The approved bremelanotide product is administered as a 1.75 mg subcutaneous injection, as needed, at least 45 minutes before anticipated activity, capped at one dose per 24 hours and eight per month — per the label, for premenopausal HSDD only [7]. This digest reports that schedule as a documented fact and offers no personal administration instruction or recommendation.

---

A regulatory-careful reading room on PT-141 (bremelanotide): the single 2019 approval for premenopausal HSDD held distinct from every off-label and research-chemical use, each figure logged to the trials or the FDA label — a reading desk organized around the prescription record, never a place that writes, fills, or fulfils one.